“Increase in R&D spending, growth of in the pharmaceutical and biotechnology industries and increasing number of CROs are driving the overall growth of the clinical trial imaging market”
The global clinical trial imaging market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 7.6% during the forecast period. Market growth is driven by factors such as the growth in the pharmaceutical and biotechnology industries, increase in R&D spending and increasing number of CROs. On the other hand, the high implementation cost of imaging system and high cost of clinical trials are the major factors hampering the growth of this market.
“The service segment accounted for the highest growth rate in the clinical trial imaging market, by product, during the forecast period”
The clinical trial imaging market is segmented into services and software based on product and service. In 2020, the service segment accounted for the highest growth rate in the clinical trial imaging market. increase in R&D spending and growth in pharmaceutical and biotechnology industries are major factor contributing to the growth of this segment.
“Medical device manufacturers segment accounted for the highest CAGR”
Based on end user, the clinical trial imaging market is segmented into pharmaceutical companies, biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes and other end users. In 2020, the medical device manufacturers segment accounted for the highest growth rate. This can be attributed to the increasing number of CROs, increase R&D spending and growth in the pharmaceutical and biotechnology industries.
“Asia Pacific: The fastest-growing region clinical trial imaging market”
The global clinical trial imaging market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as the growth in the pharmaceutical and biotechnology industries and increase in R&D spending are driving the growth of the clinical trial imaging market in this region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
- By Designation: C-level – 27%, D-level – 18%, and Others – 55%
- By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:
- ICON plc. (Ireland)
- BioTelemetry Inc. (US)
- Biomedical Systems Corporation (US)
- Medpace Holdings, Inc. (US)
- IXICO plc. (UK)
- Resonance Health Ltd. (Australia)
- Radiant Sage LLC. (US)
- BioClinica Inc. (US)
- Intrinsic Imaging LLC. (US)
- Cardiovascular Imaging Technologies LLC. (US)
- Medical Metrics Inc. (US)
- Prism Clinical Imaging, Inc. (US)
- Boston Imaging Core Lab LLC. (US)
- anagram 4 clinical trials (Spain)
- Lyscaut Medical Imaging Company (Belgium)
- Calyx Group (UK)
- Bioseptive Inc. (Canada)
- ProScan Imaging LLC. (US)
- Micron Inc. (Japan)
- Imaging Endpoints LI, LLC (US)
- Perspectum Ltd. (UK)
- PharmtraceklinischeEntwicklung GmbH (Germany)
- WorldCare Clinical, LLC (US)
Research Coverage:
This report provides a detailed picture of the global clinical trial imaging market. It aims at estimating the size and future growth potential of the market across different segments, such as product and service, modality, therapeutic area, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its sub segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.